Globus Medical Inc
NYSE:GMED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (23.8), the stock would be worth $99.19 (5% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.7 | $94.38 |
0%
|
| 3-Year Average | 23.8 | $99.19 |
+5%
|
| 5-Year Average | 31.3 | $130.26 |
+38%
|
| Industry Average | 19.2 | $80.14 |
-15%
|
| Country Average | 19.6 | $81.69 |
-13%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$11.4B
|
/ |
Jan 2026
$537.7m
|
= |
|
|
$11.4B
|
/ |
Dec 2026
$796.8m
|
= |
|
|
$11.4B
|
/ |
Dec 2027
$892.4m
|
= |
|
|
$11.4B
|
/ |
Dec 2028
$978.6m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Globus Medical Inc
NYSE:GMED
|
12.7B USD | 22.7 | 23.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 55.5 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 19.1 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 24 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 18.9 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 26.6 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 15 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 25.7 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 33 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 16.8 | 25.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.8 | 21.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Globus Medical Inc
Glance View
Globus Medical Inc., founded in 2003, has crafted a distinctive narrative in the landscape of medical technology, rooted in innovation and practicality. Emerging from a profound understanding of spinal pathologies, the company has steadily risen to become a pivotal player in the musculoskeletal sector. Its journey is steered by a commitment to addressing complex spine disorders through the development of cutting-edge products that are not only innovative but also substantially user-friendly for both surgeons and patients. This fusion of technology and practicality is what sets Globus Medical apart. The company relentlessly focuses on expanding its product offerings through significant investments in research and development, continuously pushing the envelope in areas such as minimally invasive surgery, advanced surgical approaches, and imaging, which form the core of its business operations. The heart of Globus Medical's revenue model lies in its expansive product portfolio that serves surgeons and healthcare institutions globally. Their financial engine is powered by the sales of implants and related surgical instruments, meticulously designed to improve surgical outcomes. These products span a wide array of offerings including but not limited to advanced minimally invasive techniques and sophisticated trauma solutions. Beyond the traditional revenue streams, Globus Medical has ventured into promising areas like robotic surgery, thereby augmenting its revenue sources while accessing the benefits of technological advancements. This strategic direction not only strengthens its market position but also ensures it stays at the forefront of providing value-based solutions in the ever-evolving healthcare landscape. By integrating its technological prowess with a deep understanding of clinical needs, Globus Medical continues to carve a robust path for sustainable growth and leadership in the medtech sector.